Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer

Table 2 Multivariate analyses of overall survival

Factors		Univariate analysis			Multivariate analysis
		HR	95%CI	P value	HR	95%CI	P value
Overall survival
Histological arm	Adenocarcinoma (r)	1.000
	SCC	1.196	0.972-1.471	0.089
Sex	Female (r)	1.000
	Male	0.983	0.807-1.196	0.983
Subsite	Oesophagus (r)	1.000
	OGJ	0.988	0.853-1.145	0.876
Liver mets	No (r)	1.000			1.000
	Yes	1.671	1.433-1.948	< 0.001	1.581	1.341-1.863	< 0.001
Peritoneal mets	No (r)	1.000			1.000
	Yes	2.290	1.583-3.314	< 0.01	2.190	1.503-3.191	< 0.001
ALP	< 100 U/I (r)	1.000			1.000
	≥ 100 U/I	1.608	1.357-1.908	< 0.001	1.287	1.072-1.544	0.007
Performance score	0-1 (r)	1.000			1.000
	2-3	2.140	1.754-2.611	< 0.001	1.703	1.374-2.110	< 0.001
Treatment arm	EOX (r)	1.000
	EOF	1.122	0.848-1.484	0.420
	ECX	1.139	0.862-1.505	0.361
	ECF	1.175	0.916-1.506	0.204
	MCF	1.176	0.870-1.589	0.291
	PVI 5FU + MMC	2.107	1.461-3.040	< 0.001
	PVI 5FU	2.132	1.481-3.067	< 0.001
	Overall			< 0.001
Study	Trial 3[10] (r)	1.000			1.000
	Trial 1[15]	0.993	0.804-1.228	0.951	1.034	0.830-1.288	0.763
	Trial 2[16]	1.850	1.432-2.390	< 0.001	1.736	1.326-2.271	< 0.001
	Overall			< 0.001			< 0.001

All variables with a P-value of less than 0.2 in univariate analyses were entered into a multivariate model in a forward stepwise manner. r: Reference; mets: Metastases; SCC: Squamous cell carcinoma; OGJ: Oesophagogastric junction; PVI: Protracted venous infusion; MMC: Mitomycin C.